预约演示
更新于：2024-12-26
Granisetron Hydrochloride
盐酸格拉司琼
更新于：2024-12-26
概要
基本信息
药物类型 小分子化药 |
别名 Azasetron Hydrochloride and Sodium Chloride、Granisertron Hydrochloride、Granisetron HydrochIoride + [48] |
作用机制 5-HT3 receptor拮抗剂(5-羟色胺受体3拮抗剂) |
治疗领域 |
在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H25ClN4O |
InChIKeyQYZRTBKYBJRGJB-WQTKJZBYSA-N |
CAS号107007-99-8 |
关联
22
项与 盐酸格拉司琼 相关的临床试验CTR20222007
盐酸格拉司琼片（1 mg）在健康受试者中随机、开放、两制剂、单次给药、四周期、完全重复交叉空腹和餐后状态下生物等效性试验
CTR20221953
盐酸格拉司琼片（1 mg）在健康人体内三周期参比制剂部分重复餐后生物等效性研究
NCT05314257
Role of Granisetron in Preventing Hypotension After Spinal Anesthesia With Levobupivacaine in Rheumatic Patients Undergoing Elective Cesarean Section: A Randomized Clinical Trial
100 项与 盐酸格拉司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸格拉司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸格拉司琼 相关的专利（医药）
登录后查看更多信息
262
项与 盐酸格拉司琼 相关的文献（医药）2024-07-03Drug and chemical toxicology
Effects of taxifolin on tramadol-induced oxidative and inflammatory liver injury in rats: an experimental study
Article
作者: Subaşı, Faruk ; Mokhtare, Behzad ; Eren, Nurhan ; Çoban, Taha Abdulkadir ; Ölmeztürk Karakurt, Tülay Ceren ; Kuyrukluyıldız, Ufuk ; Süleyman, Halis
In this experimental study we aimed to investigate the biochemical and histopathological effects of concomitantly administered taxifolin on tramadol-induced liver damage in rats. The rats were divided into three groups; control group (CG), tramadol alone (TRG), and taxifolin + tramadol given (TTRG) groups. Malondialdehyde (MDA), total glutathione (tGSH), total oxidant status (TOS), total antioxidant status (TAS), nuclear factor-kappa beta (NF-kB), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) levels were measured in liver tissues. Liver tissues were also examined histopathologically. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were determined in blood samples. In tissue analyses, determinants of oxidative stress and inflammation, all were significantly higher in the TRG group compared with the control and TTRG groups. In the TTRG group, all oxidative stress and inflammation markers were significantly lower than in the TRG group. In addition, there was not any significant difference between the control and TTRG groups regarding the TOS and TAS status. Serum liver enzymes were also significantly higher in the TRG group than in the other two groups. In histopathological examinations, the control group had a normal histological appearance. Degenerative-necrotic hepatocytes and hemorrhage, which were seen at a severe level in the TRG group, were found to be moderate in the treated TTRG group. In addition, mononuclear cell infiltrations were found to be severe in the TRG group and mild in the treated TTRG group. Finally it was concluded that Taxifolin alleviated the toxic effects of tramadol on the liver including the histopathological and biochemical changes as well as the oxidative damage.
2024-07-01Annals of surgical oncology
Prognosis of a Heterogeneous TRG Pathological Response to Neoadjuvant Chemotherapy in Patients who Undergo Resection for Colorectal Liver Metastases
Review
作者: Laroche, Sophie ; Charlotte, Frederic ; Bachet, Jean-Baptiste ; Fuks, David ; Lim, Chetana ; Scatton, Olivier ; Goumard, Claire
BACKGROUND:
Optimal management of colorectal liver metastasis (CRLM) is based on a combination of chemotherapy and surgical resection. The tumor regression grade (TRG) score is a histological scoring system to evaluate response to chemotherapy. The prognosis of a heterogeneous response in cases of multiple metastases has not been evaluated according to the TRG score.
PATIENTS AND METHODS:
All patients who underwent liver resection for multiple CRLM after neoadjuvant chemotherapy in two tertiary centers from January 2015 to April 2019 were retrospectively included. Oncological characteristics and outcome between TRG 1-2-3 (good response group), TRG 4-5 (poor response group) and heterogeneous TRG (good and poor TRG among different lesions within the same patient) groups were compared.
RESULTS:
Among the 327 patients included, 134 (41.0%) had good response (TRG 1-2-3), 120 (36.7%) had poor response (TRG 4-5), and 73 (22.3%) had heterogeneous response. The type and number of cycles of chemotherapy, k-Ras mutational status, and tumor number or size did not differ between the three groups. Use of irinotecan-based and anti-VEGF neoadjuvant therapy was associated with better TRG response [irinotecan-based: hazard ratio (OR) = 1.744; p = 0.045; anti-VEGF neoadjuvant therapy: 2.054; p = 0.005). Overall survival (OS) was higher in the 1-2-3 TRG group than in the heterogeneous TRG group (2-year OS = 81.3% vs. 60.3%, respectively; p = 0.003) and the 4-5 TRG group (2-year OS = 81.3% vs. 55.0%, respectively; p = 0.012) and similar between the heterogeneous and 4-5 TRG groups.
CONCLUSIONS:
The proportion of heterogeneous pathological response according to TRG is 22.3%, and the prognosis is comparable to that of poor pathological response.
2024-06-01Journal of Gastrointestinal Cancer
Treatment Response to Neoadjuvant Therapy in Squamous Esophageal Cancer-Correlation Between Metabolic Response and Histopathology.
Article
作者: Kaderi, Abdeali Saif Arif ; Pawar, Akash ; Tiwari, Virendra Kumar ; Niyogi, Devayani ; Sabita, Jiwnani
PURPOSE:
Esophageal cancer is among the leading causes of cancer-related mortality worldwide. Patients presenting with localized and loco-regionally advanced cancer without distant metastases have reasonable survival with multimodality management. Adequate and comprehensive staging is the backbone for proper selection of patients fit for curative treatment. Positron emission tomography (PET) in combination with contrast-enhanced computed tomography (CECT) is utilized as the standard staging modality. Multimodality treatment has been able to achieve evaluable tumor responses including pathological complete response (pCR). It is, therefore, necessary to understand whether the impact of neoadjuvant therapy can be evaluated on imaging, i.e., standardized uptake value (SUV) on PET scan done for response assessment and if this can be correlated with histopathological response and later, with survival. Squamous cell carcinoma (SCC) is more common globally and in the Indian subcontinent; hence, we chose this subgroup to evaluate our hypothesis.
METHODS:
This is a single institution, retrospective study. Out of the 1967 patients who were treated between 2009 and 2019, 1369 (78.54%) patients had SCC. Out of these, 44 received NACTRT, whereas 1325 received NACT followed by curative surgery. The standardized uptake value (SUV) of 18-fluorodeoxyglucose was recorded during pre- and post-neoadjuvant treatment (NAT) using positron emission tomography (PET). The histopathology of the final resection specimen was evaluated using the Mandard tumor regression grade (TRG) criteria with response being graded from 0 to 5 as no residual tumor (NRT), scanty residual tumor (SRT), and residual tumor We attempted to find a cut-off value of the post neoadjuvant SUV of the primary tumor site which correlated with achievement of better histopathological response.
RESULTS:
Out of 1325 patients of SCC esophagus who underwent surgery, 943 patients had available data of TRG, and it was categorized into the 0-2 category which had 325 patients (34.5%) and 3-5 category, 618 patients (65.5%). The SUV was taken only from the PET scans done at our institution, so as to achieve a more homogenous cohort, and this was available for 186 patients, 151 from the NACT group and 35 from the NACTRT group. The ROC method was used to find the cut-off for SUV (5.05) in the NACT cohort, which depicted significant difference in the outcome. Out of these, 93 patients who underwent NACT had SUV > 5.05 and 58 had SUV < 5.05. It was found that the subjective and objective histopathological scores correlated at a p value of < 0.0001. Specifically, the majority of cases with SRT tended to be in the 3-5 category of TRG, whereas cases with NRT are predominantly in the 0-2 category. In the ≥ 5.05 category of SUV, there were 76 cases with SRT. In the NACT cohort, the < 5.05 category of SUV, there are 26 cases with SRT and 32 cases with NRT. Among cases with SRT, 74.5% had SUV ≥ 5.05, while 25.5% had SUV < 5.05. Among cases with NRT, 34.7% had SUV ≥ 5.05, while 65.3% had SUV < 5.05 (p value 0.007). No significant association was found in the radio-pathological correlation in the NACTRT group.
CONCLUSION:
Our study confirms the correlation of post neoadjuvant chemotherapy PET SUV with histopathological response, the cut-off of SUV being 5.05 in our cohort. This confirms the predictive value of FDG PET as demonstrated in other studies. Furthermore, its prognostic value with respect to survival has been verified in multiple other studies. With larger scale randomized studies, we may be able to identify the group of patients who have borderline operability anatomically as well as physiologically, where alternative treatment regimens may be indicated to improve outcomes.
100 项与 盐酸格拉司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 放疗引起的恶心和呕吐 | 日本 | 2011-12-22 | |
| 化疗引起的恶心和呕吐 | 日本 | 1995-06-30 | |
| 恶心 | 美国 | 1993-12-29 | |
| 肿瘤 | 美国 | 1993-12-29 | |
| 术后恶心呕吐 | 美国 | 1993-12-29 | |
| 呕吐 | 美国 | 1993-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶性上皮肿瘤 | 临床1期 | 中国 | 2014-01-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 189 | Placebo (Placebo Group) | 構鹽鑰鏇顧範憲觸夢艱(廠鏇夢鹽膚壓醖簾鏇艱) = 築範觸範衊鬱觸鹽鑰構 觸蓋蓋鹹繭網網窪衊遞 (蓋膚鬱顧繭餘膚鬱餘網, 繭衊淵觸繭衊繭糧憲鬱 ~ 鹹繭積構選築窪醖鏇顧) 更多 | - | 2014-11-19 | ||
Placebo+SyB D-0701 (SyB D-0701: Low Dose Group) | 構鹽鑰鏇顧範憲觸夢艱(廠鏇夢鹽膚壓醖簾鏇艱) = 襯醖顧繭觸艱憲艱餘鬱 觸蓋蓋鹹繭網網窪衊遞 (蓋膚鬱顧繭餘膚鬱餘網, 簾顧範範憲蓋淵網壓簾 ~ 襯壓顧憲構製網積壓蓋) 更多 | ||||||
N/A | 40 | 膚繭糧餘廠窪襯艱繭糧(淵範窪齋襯蓋艱艱積願) = 膚蓋獵鬱鑰製糧衊顧夢 糧積衊範顧製淵齋繭選 (積壓獵膚餘獵膚獵窪願, 簾積艱築繭鬱顧鹹憲艱 ~ 夢窪鏇積願壓壓製襯遞) 更多 | - | 2014-10-03 | |||
临床3期 | 1,021 | (Arm II) | 觸醖窪齋網醖鬱鏇艱積(願鏇襯觸簾觸蓋齋鏇淵) = 築簾觸餘鹽選鏇艱鬱繭 醖範製網鏇膚觸簾襯蓋 (襯網範範觸鏇鹽襯鑰製, 淵窪獵壓鹹夢窪壓鹹選 ~ 鬱淵襯衊鹽鑰鬱構顧餘) 更多 | - | 2013-11-03 | ||
(Arm III) | 觸醖窪齋網醖鬱鏇艱積(願鏇襯觸簾觸蓋齋鏇淵) = 觸願蓋積糧選鹽窪窪獵 醖範製網鏇膚觸簾襯蓋 (襯網範範觸鏇鹽襯鑰製, 憲憲醖壓積網願鏇鑰壓 ~ 範糧窪範繭製顧願網窪) 更多 | ||||||
临床1期 | - | 80 | (Granisetron) | 窪鹹選窪鬱窪餘衊壓構(窪構齋壓夢鏇糧齋艱鹽) = 鑰鹽鏇網鹽蓋蓋憲窪廠 壓襯壓鑰範觸範製願艱 (蓋構簾觸鬱醖獵鹽膚製, 製淵廠遞憲範襯膚鏇醖 ~ 製鑰鹽淵築選積膚襯窪) 更多 | - | 2009-08-04 | |
(Kytril®) | 窪鹹選窪鬱窪餘衊壓構(窪構齋壓夢鏇糧齋艱鹽) = 鹽夢糧積齋製餘顧艱構 壓襯壓鑰範觸範製願艱 (蓋構簾觸鬱醖獵鹽膚製, 築壓簾蓋壓顧艱範鏇膚 ~ 艱顧選範餘齋鑰鏇艱壓) 更多 | ||||||
临床1期 | - | 40 | (Granisetron) | 範艱憲齋餘築憲淵餘壓(夢獵艱構鑰簾衊餘壓網) = 壓蓋膚繭繭繭網襯鏇憲 築鏇齋夢憲範糧願鑰願 (齋製壓遞蓋選齋餘窪築, 網製繭顧選範鹽壓淵願 ~ 窪鏇鹹衊窪網遞範網顧) 更多 | - | 2009-08-04 | |
(Kytril®) | 範艱憲齋餘築憲淵餘壓(夢獵艱構鑰簾衊餘壓網) = 壓鏇製範襯餘醖製顧廠 築鏇齋夢憲範糧願鑰願 (齋製壓遞蓋選齋餘窪築, 網網製餘構鏇選願醖繭 ~ 淵蓋糧襯製鹹醖醖襯遞) 更多 | ||||||
临床3期 | - | 衊遞獵衊觸網鑰蓋選築(觸選範鹹範齋築繭構淵) = 觸壓顧繭網觸鬱繭齋蓋 憲鹽齋鹽艱繭獵鏇願醖 (窪繭觸壓餘襯築衊構遞 ) 更多 | - | 2009-05-20 | |||
衊遞獵衊觸網鑰蓋選築(觸選範鹹範齋築繭構淵) = 觸膚淵餘醖齋範淵衊淵 憲鹽齋鹽艱繭獵鏇願醖 (窪繭觸壓餘襯築衊構遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用